Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Prism Medico and Pharmacy Ltd, at its meeting held on 14 August 2025, approved the unaudited standalone financial results for the quarter ended 30 June 2025 along with the limited review report from auditors. Revenue from operations jumped sharply to ₹158.87 lakhs in Q1 FY26 from just ₹7.28 lakhs in Q1 FY25. Total income rose to ₹158.91 lakhs versus ₹8.37 lakhs in the year-ago quarter. Net profit for the quarter stood at ₹65.73 lakhs, up from ₹4.15 lakhs in Q1 FY25, with basic and diluted EPS of ₹0.0108. The full FY25 (audited) had ended with a marginal net loss of ₹2.13 lakhs, so the company has swung into solid profitability this quarter. Total expenses scaled up to ₹93.84 lakhs, driven mainly by cost of materials consumed at ₹85.75 lakhs.
A dramatic revenue jump and return to profitability are positive for shareholders, but the very low base in the year-ago quarter means investors should look for sustained performance in coming quarters before reading this as a structural turnaround.